{
    "nctId": "NCT06533332",
    "briefTitle": "A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors",
    "officialTitle": "A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Advanced Solid Tumor, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Endometrial Cancer, Metastatic Liver Cancer, Metastatic Pancreatic Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Incidence of Dose Limiting Toxicities of ERX-315",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients must be at least 18 years of age at the time of signing the informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Patients must have histologically or cytologically confirmed solid tumor, primarily including but not limited to breast, ovarian, pancreatic, endometrial and hepatocellular carcinoma, that is advanced unresectable and/or metastatic disease for whom standard therapies do not exist or are no longer effective\n* Patients must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.\n* Adequate baseline organ function and hematologic function\n* Life expectancy \\>3 months\n\nExclusion Criteria:\n\n* Systemic anti cancer therapy within 4 weeks of first dose of study drug\n* Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug.\n* Uncontrolled intercurrent illnesses\n* Known history of LIPA deficiency, such as Wolman disease or Cholesterol ester storage disease.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}